Tezosentan (an intravenous endothelin receptor A/B antagonist) reduces peripheral resistance and increases cardiac power therefore preventing a steep decrease in blood pressure in patients with congestive heart failure

European Journal of Heart Failure

Volumn 3, Issue 4, 2001, Pages 457-461

  Cotter, Gad ^a   Kiowski, Wolfgang ^b   Kaluski, Edo ^a   Kobrin, Isaac ^c   Milovanov, Olga ^a   Marmor, Alon ^d   Jafari, Jamal ^e   Reisin, Leonardo ^e   Krakover, Ricardo ^a   Vered, Zvi ^a   Caspi, Avi ^f  

^a Cardiology Institute   (Israel)

^b UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^c ACTELION PHARMACEUTICALS LTD   (Switzerland)

^d Rebecca Sieff Government Hospital   (Israel)

^e Ashkelon Hospital   (Israel)

^f KAPLAN HOSPITAL   (Israel)

Author keywords

Blood pressure; Congestive heart failure; Tezosentan

Indexed keywords

ENDOTHELIN RECEPTOR ANTAGONIST; NESIRITIDE; NITRIC ACID DERIVATIVE; PLACEBO; TEZOSENTAN; UNCLASSIFIED DRUG;

ADULT; AGED; ANALYTIC METHOD; ARTICLE; BLOOD PRESSURE; CLINICAL ARTICLE; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG EFFECT; FEMALE; HEART EJECTION FRACTION; HEART FUNCTION; HEART INDEX; HEART LEFT VENTRICLE FAILURE; HUMAN; HYPOTENSION; LUNG CAPILLARY PRESSURE; MALE; MEAN ARTERIAL PRESSURE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; VASCULAR RESISTANCE;

ADULT; AGED; BLOOD PRESSURE; CONFIDENCE INTERVALS; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; FEMALE; FOLLOW-UP STUDIES; HEART FAILURE, CONGESTIVE; HEART FUNCTION TESTS; HUMANS; HYPOTENSION; INFUSIONS, INTRAVENOUS; MALE; MIDDLE AGED; PROBABILITY; PYRIDINES; RECEPTORS, ENDOTHELIN; REFERENCE VALUES; SEVERITY OF ILLNESS INDEX; STROKE VOLUME; TETRAZOLES; TREATMENT OUTCOME; VASCULAR RESISTANCE;

EID: 0034893420     PISSN: 13889842     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1388-9842(01)00168-4     Document Type: Article

References (15)

1. Exercise capacity in patients with severe left ventricular dysfunction
2. Lack of correlation between exercise capacity and indexes of resting left ventricular performance in heart failure
3. Factors determining symptoms in heart failure: Comparison of fast and slow exercise tests
4. Clinical and research implications of new concepts in the assessment of cardiac pumping performance in heart failure
5. The dual endothelin-receptor antagonist tezosentan acutely improves hemodynamic parameters in patients with advanced heart failure
6. Nitroglycerin in acute myocardial infarction. X. Effect of small and large doses of nitroglycerin on sigma ST segment deviation - Experimental and clinical results
7. Intravenous nitroglycerin therapy to limit myocardial infarct size, expansion, and complications. Effect of timing, dosage, and infarct location
8. High-dose nitrates in the immediate management of unstable angina: Optimal dosage, route of administration, and therapeutic goals
9. Central and regional hemodynamic effects of intravenous isosorbide dinitrate, nitroglycerin and nitroprusside in patients with congestive heart failure
10. Intravenous nesiritide, a natriuretic peptide in the treatment of decompensated congestive heart failure
11. Acute hemodynamic and neurohumoral effects of selective ET(A) receptor blockade in patients with congestive heart failure
12. Acute endothelin A receptor blockade causes selective pulmonary vasodilation in patients with chronic heart failure
13. Pathophysiology of endothelin in the cardiovascular system
14. Endogenous endothelin-1 depresses left ventricular systolic and diastolic performance in congestive heart failure
15. Contrasting inotropic effects of endogenous endothelin in the normal and failing human heart: Studies with an intracoronary ET(A) receptor antagonist